Putnam Investments’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Putnam Investments’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,984	Closed	-$290K	–	1216
2022 Q3	$290K	Buy	10,984 +2,051	+23%	+$75.3K	﹤0.01%	1085
2022 Q2	$397K	Sell	8,933 -108	-1%	-$4.96K	﹤0.01%	998
2022 Q1	$448K	Sell	9,041 -651	-7%	-$31.2K	﹤0.01%	1040
2021 Q4	$493K	Buy	+9,692	New	+$502K	﹤0.01%	1030
2017 Q2	–	Sell	-78,412	Closed	-$6.5M	–	1322
2017 Q1	$6.5M	Sell	78,412 -27,844	-26%	-$2.07M	0.02%	500
2016 Q4	$8.43M	Buy	106,256 +14,981	+16%	+$1.09M	0.02%	417
2016 Q3	$6.39M	Sell	91,275 -24,745	-21%	-$1.37M	0.02%	492
2016 Q2	$4.5M	Buy	116,020 +22,912	+25%	+$954K	0.01%	663
2016 Q1	$3.77M	Buy	93,108 +8,658	+10%	+$549K	0.01%	757
2015 Q4	$7.49M	Buy	84,450 +27,100	+47%	+$2.14M	0.02%	540
2015 Q3	$4.25M	Buy	57,350 +18,150	+46%	+$1.51M	0.01%	727
2015 Q2	$3.17M	Buy	+39,200	New	+$2.55M	0.01%	900

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

SGCIA

Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Putnam Investments's EGRX Position: Q4 2022 in Review

Putnam Investments sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2022, closing a stake of 10,984 shares — an estimated $290K sold.

Putnam Investments first reported a position in EGRX in Q2 2015 and held it in 12 quarters. The position peaked at $8.43M in Q4 2016. 152 funds tracked by Wall St. Rank hold EGRX as of Q4 2022.

Putnam Investments reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
Putnam Investments sold 10,984 Eagle Pharmaceuticals, Inc. shares in Q4 2022, an estimated $290K.
Putnam Investments first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 12 quarters.
Putnam Investments's Eagle Pharmaceuticals, Inc. position peaked at $8.43M in Q4 2016.
152 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2022.

Based on Putnam Investments's 13F filing for Q4 2022, filed 14 Feb 2023.